Antibody Therapeutics Market

Antibody Therapeutics Market by Format (Monoclonal, Polyclonal, Antibody Fragment, Bispecific), Disease Area (Oncology, Autoimmune & Inflammatory, Neurology, Hematology, Infectious), Source (Human, Chimeric), Route (IV, SC) & Region - Global Forecast to 2028

Report Code: PH 8876 Dec, 2023, by marketsandmarkets.com

The global antibody therapeutics market in terms of revenue was estimated to be worth $247.3 billion in 2023 and is poised to reach $479.0 billion by 2028, growing at a CAGR of 14.1% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Growth in this market is mainly due to the growing initiatives towards advancements in antibody engineering. Additionally, factors such as growing demand for oncology antibody therapeutics and a growing clinical pipeline focus on antibody therapeutics are supporting the growth of this market. Moreover, developing economies are expected to create lucrative offers for the growth of this market.

Attractive Opportunities in the Antibody Therapeutics Market

Antibody  Therapeutics Market

To know about the assumptions considered for the study, Request for Free Sample Report

Antibody  Therapeutics Market

Antibody Therapeutics Market Dynamics

Driver: Growing advancements in antibody engineering

Antibody engineering is a specialized field that focuses on modifying antibodies to enhance their therapeutic properties. This process involves the application of technology and techniques to design antibodies with specific characteristics tailored for therapeutic applications. Antibody engineering offers several benefits such as customization for specific therapeutic indications, targeted effects and more. Severa antibody engineering techniques are being used for the production of antibody fragments. These include hybridoma technology, Phage Display, Single B-Cell Technology, and Transgenic Animals. Wacker's ESETEC secretion technology (by Wacker Chemie AG) is an approach for the expression and secretion of antibody fragments (Fab) exceeding 4.0 g/L and scFv exceeding 3.5 g/L into the fermentation broth. Another platform for the productive creation of a sizable number of antibody fragments is the Pelican Expression Technology Platform (by Ligand Pharmaceuticals) and the pOP prokaryotic expression vector. Such advancements in technology allow the development of novel antibody therapeutics, thus, supporting market growth.

Restraint: Stringent regulatory approval process

The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are the major regulatory authorities that regulate the commercialization of antibody therapeutics. The stringent regulatory guidelines imposed by the FDA in the US and the EMA in Europe during clinical trials have the potential to create significant restraints for companies. There have been instances of product regulatory rejections or withdrawals due to stringent regulatory parameters for antibody therapeutics. For instance, in December 2022, Y-mAbs Therapeutics issued a complete response letter (CRL) for the Biologics License Application (BLA) for the investigational medicine 131I-omburtamab (omburtamab) for the treatment of CNS/leptomeningeal metastasis from neuroblastoma for which the FDA completed the review of the application and concluded that it is unable to approve the BLA in its then presented form. Thus, the market players are required to mandatorily follow regulations put forth by the regulatory bodies to overcome this restraint.

Opportunity: Increasing collaboration of pharmaceutical companies with CROs, CDMOs and academic institutions

Market players are increasingly focusing on a collaborative approach with an aim to enhance their market position. This collaborative approach allows players to leverage the research and manufacturing capabilities as well as professional expertise from these organizations thus creating new avenues of growth for market players. For instance, AstraZeneca in collaboration with the University Health Network, Toronto, has been engaged in a phase II, open-label study to assess the efficacy of AZD2936 in terms of molecular residual disease (MRD) clearance and treatment outcome in patients with MRD after definitive treatment for high-risk locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). Such

Challenge: Complexities in manufacturing processes

Manufacturing processes for antibody therapeutics involve several complexities with some challenges that impact production capacity and efficiency. For instance, bacterial systems can synthesize inactive proteins with the proper molecular structure, which can result in the creation of inclusion bodies. Additionally, bacteria can eliminate signal peptides but not preproteins like native coagulation growth factors, which they cannot break down. The purification process is challenging because endotoxins, which are created by bacteria during expression, are notoriously difficult to eliminate. Endotoxins and inclusion bodies present a hurdle to the final product's purity. Monoclonal antibodies which are the primary class of therapeutic antibodies, are large and complex molecules. Their manufacturing involves intricate processes due to the complicated nature of these molecules, presenting challenges distinct from small molecules, oral medicines, or vaccines. Therefore, low yields, protein misfolding, aggregation, post-translational modifications, immunogenicity, regulatory compliance, cost of goods, time-to-market, and process reproducibility are critical factors that can impact the efficiency, affordability, and accessibility of these therapies. Thus, market players also outsource manufacturing from service providers. This adds to the burden of costs incurred in manufacturing which creates a further challenge of manufacturing economically.

Antibody Therapeutics Market Ecosystem

Prominent companies in the market include companies operating in the market for several years and possessing a diversified product portfolio, state-of-the-art technologies, and strong global sales and marketing networks. Prominent companies in the antibody therapeutics industry include F. Hoffmann-La Roche Ltd. (Switzerland), AbbVie Inc. (US), Johnson & Johnson (US), Merck KGaA (Germany), Bristol-Myers Squibb (US), AstraZeneca (UK), Sanofi (France), Regeneron Pharmaceuticals, Inc. (US), Novartis AG (Switzerland), Amgen, Inc. (US), Biogen Inc. (US) among others.

Antibody  Therapeutics Market Ecosystem

The monoclonal antibodies accounted for the largest share of the format segment in the overall antibody therapeutics industry in 2023.

On the basis of format, the antibody therapeutics market is segmented into monoclonal antibodies, polyclonal antibodies, antibody fragments, bispecific antibodies, and other novel antibody therapies. In 2022, the monoclonal antibodies segment accounted for the largest share of the market. The presence of a large number of pipeline monoclonal antibodies and the specificity of the target offered by mAbs are the major factors driving the market growth of this segment.

The autoimmune and inflammatory disorders segment dominated the disease area segment in the antibody therapeutics industry in 2023.

On the basis of disease area, the antibody therapeutics market is segmented into autoimmune & inflammatory diseases, oncology, hematology, infectious diseases, osteology, immunology, neurology, and other disease areas. In 2022, the autoimmune & inflammatory diseases segment accounted for the largest share of the market. This can be attributed to one of the major factors- the presence of a large number of marketed antibody therapeutics against autoimmune & inflammatory conditions.

North America was the largest market for overall antibody therapeutics industry in 2022 and also during the forecast period.

Geographically, the antibody therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. The market was dominated by North America in 2022 and this dominance is anticipated to continue throughout the forecast period between 2023 and 2028. The market for antibody therapeutics is expanding in the region as a result of factors like major antibody therapeutics sales revenue generated from the region and availability of advanced infrastructure in hospitals among others.

Antibody  Therapeutics Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The prominent players in the antibody therapeutics market are F. Hoffmann-La Roche Ltd. (Switzerland), AbbVie Inc. (US), Johnson & Johnson (US), Merck KGaA (Germany), Bristol-Myers Squibb (US), AstraZeneca (UK), Sanofi (France), Regeneron Pharmaceuticals, Inc. (US), Novartis AG (Switzerland), Amgen, Inc. (US), Biogen Inc. (US) among others.

Scope of the Antibody Therapeutics Industry

Report Metric

Details

Market Revenue in 2023

$247.3 billion

Projected Revenue by 2028

$479.0 billion

Revenue Rate

Poised to Grow at a CAGR of 14.1%

Market Driver

Growing advancements in antibody engineering

Market Opportunity

Increasing collaboration of pharmaceutical companies with CROs, CDMOs and academic institutions

All the market segments have been divided for the Antibody Therapeutics market to forecast revenue and analyze trends in each of the following submarkets:

By Format

  • Monoclonal antibody
  • Polyclonal antibody therapy
  • Bispecific antibody
  • Antibody fragment
  • Other antibody formats

By Disease Areas

  • Autoimmune & inflammatory diseases
  • Oncology
  • Hematology
  • Infectious diseases
  • Osteology
  • Immunology
  • Neurology
  • Other disease areas

By Route of Administration

  • Intravenous
  • Subcutaneous
  • Other routes of administration

By Source

  • Human
  • Humanized
  • Chimeric
  • Other sources

By End User

  • Hospitals
  • Long-term care facilities
  • Other end users

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia Pacific (RoAPAC)
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East
  • Africa

Recent Developments of Antibody Therapeutics Industry

  • In October 2023, F. Hoffmann-La Roche Ltd. entered into a definitive agreement to acquire Televant. Through this agreement, Roche received the development, manufacturing and commercialization rights in the US and Japan for Telavant’s RVT-3101, a novel TL1A directed antibody.
  • In January 2023, AbbVie Inc. and Immunome, Inc. entered into strategic collaboration to identify up to 10 novel target-antibody pairs leveraging Immunome's Discovery Engine.
  • In December 2022, AbbVie Inc. and HotSpot Therapeutics entered into a strategic collaboration and option to license agreement for HotSpot’s discovery-stage IRF5 program for the treatment of autoimmune diseases.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 26)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
                    FIGURE 1 ANTIBODY THERAPEUTICS MARKET SEGMENTATION
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
    1.5 STAKEHOLDERS 
    1.6 RECESSION IMPACT 
 
2 RESEARCH METHODOLOGY (Page No. - 29)
    2.1 RESEARCH DATA 
          FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 3 ANTIBODY THERAPEUTICS INDUSTRY: BREAKDOWN OF PRIMARIES
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
          FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
           2.2.1 INSIGHTS FROM PRIMARIES
                    FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
                    FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
    2.3 GROWTH FORECAST 
          FIGURE 8 MARKET: CAGR PROJECTIONS
          FIGURE 9 MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 10 DATA TRIANGULATION METHODOLOGY
    2.5 RESEARCH ASSUMPTIONS 
    2.6 LIMITATIONS 
    2.7 RISK ANALYSIS 
    2.8 RECESSION IMPACT ANALYSIS 
          TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
 
3 EXECUTIVE SUMMARY (Page No. - 42)
    FIGURE 11 ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2023 VS. 2028 (USD BILLION)
    FIGURE 12 ANTIBODY THERAPEUTICS INDUSTRY, BY DISEASE AREA, 2023 VS. 2028 (USD BILLION)
    FIGURE 13 MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD BILLION)
    FIGURE 14 ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2023 VS. 2028 (USD BILLION)
    FIGURE 15 MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)
    FIGURE 16 GEOGRAPHICAL SNAPSHOT OF MARKET
 
4 PREMIUM INSIGHTS (Page No. - 47)
    4.1 ANTIBODY THERAPEUTICS MARKET OVERVIEW 
          FIGURE 17 INCREASING DEMAND FOR ANTIBODY THERAPIES IN TREATMENT OF CANCER TO DRIVE MARKET
    4.2 NORTH AMERICA: ANTIBODY THERAPEUTICS INDUSTRY, BY SOURCE & COUNTRY (2022) 
          FIGURE 18 HUMAN SOURCES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
    4.3 MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD MILLION) 
          FIGURE 19 INTRAVENOUS ROUTE OF ADMINISTRATION SEGMENT DOMINATED MARKET IN 2022
    4.4 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 20 GERMANY TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 50)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 21 ANTIBODY THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Advancements in antibody engineering
                    5.2.1.2 Rising demand for oncology therapeutics
                               TABLE 2 NUMBER OF APPROVED PRODUCTS BY US FDA/EMA (2015-2023)
                    5.2.1.3 Advantages offered by therapeutic antibodies
                    5.2.1.4 Increasing R&D activities for innovative therapeutics
           5.2.2 RESTRAINTS
                    5.2.2.1 Stringent regulatory requirements
           5.2.3 OPPORTUNITIES
                    5.2.3.1 High growth potential of emerging economies
                    5.2.3.2 Growing focus on collaborations for drug discovery & development
           5.2.4 CHALLENGES
                    5.2.4.1 Complexities associated with manufacturing processes
    5.3 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 3 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.3.1 THREAT OF NEW ENTRANTS
           5.3.2 THREAT OF SUBSTITUTES
           5.3.3 BARGAINING POWER OF SUPPLIERS
           5.3.4 BARGAINING POWER OF BUYERS
           5.3.5 INTENSITY OF COMPETITIVE RIVALRY
    5.4 TECHNOLOGY ANALYSIS 
    5.5 VALUE CHAIN ANALYSIS 
          FIGURE 22 ANTIBODY THERAPEUTICS MARKET: VALUE CHAIN ANALYSIS
    5.6 ECOSYSTEM ANALYSIS 
          FIGURE 23 MARKET: ECOSYSTEM MAP
    5.7 PATENT ANALYSIS 
          FIGURE 24 PATENT APPLICATIONS FOR ANTIBODY THERAPEUTIC PRODUCTS (JANUARY 2012–OCTOBER 2023)
          TABLE 4 MARKET: INDICATIVE LIST OF PATENTS
    5.8 PIPELINE ANALYSIS 
          TABLE 5 ANTIBODY THERAPEUTICS IN CLINICAL PIPELINE
    5.9 SUPPLY CHAIN ANALYSIS 
          FIGURE 25 ANTIBODY THERAPEUTICS INDUSTRY: SUPPLY CHAIN ANALYSIS
          TABLE 6 SUPPLY CHAIN ECOSYSTEM
    5.1 REGULATORY LANDSCAPE 
           5.10.1 REGULATORY ANALYSIS
           5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS, BY REGION
                     TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.11 PRICING ANALYSIS 
           5.11.1 AVERAGE SELLING PRICE TREND OF ANTIBODY THERAPEUTICS
                     TABLE 11 AVERAGE SELLING PRICE OF ANTIBODY THERAPEUTICS, BY KEY PLAYER
           5.11.2 INDICATIVE PRICING ANALYSIS
                     TABLE 12 INDICATIVE PRICING ANALYSIS OF ANTIBODY THERAPEUTIC PRODUCTS, BY ROUTE OF ADMINISTRATION
    5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
    5.13 KEY CONFERENCES AND EVENTS 
           TABLE 13 ANTIBODY THERAPEUTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2023–2024)
    5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.14.1 KEY STAKEHOLDERS ON BUYING PROCESS
                     FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR ANTIBODY THERAPEUTICS
           5.14.2 BUYING CRITERIA FOR MARKET
                     FIGURE 27 KEY BUYING CRITERIA FOR HOSPITALS AND LONG-TERM CARE FACILITIES
 
6 ANTIBODY THERAPEUTICS MARKET, BY FORMAT (Page No. - 74)
    6.1 INTRODUCTION 
          TABLE 14 ANTIBODY THERAPEUTICS INDUSTRY, BY FORMAT, 2021–2028 (USD MILLION)
    6.2 MONOCLONAL ANTIBODIES 
           6.2.1 TARGET SPECIFICITY AND GROWING CLINICAL PIPELINE OF MABS TO DRIVE MARKET
                    TABLE 15 APPROVED MONOCLONAL ANTIBODIES
                    TABLE 16 MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 17 NORTH AMERICA: MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 18 EUROPE: MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 19 ASIA PACIFIC: MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 20 LATIN AMERICA: MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
    6.3 POLYCLONAL ANTIBODIES 
           6.3.1 BROADER SPECTRUM OF TARGETS OFFERED BY POLYCLONAL ANTIBODIES TO SUPPORT MARKET GROWTH
                    TABLE 21 APPROVED POLYCLONAL ANTIBODIES
                    TABLE 22 MARKET FOR POLYCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 23 NORTH AMERICA: MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 24 EUROPE: MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 25 ASIA PACIFIC: MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 26 LATIN AMERICA: MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
    6.4 ANTIBODY FRAGMENTS 
           6.4.1 WIDE APPLICATIONS OF ANTIBODY FRAGMENTS IN ONCOLOGY TO FUEL GROWTH
                    TABLE 27 APPROVED ANTIBODY FRAGMENTS
                    TABLE 28 ANTIBODY THERAPEUTICS INDUSTRY FOR ANTIBODY FRAGMENTS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 29 NORTH AMERICA: MARKET FOR ANTIBODY FRAGMENTS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 30 EUROPE: MARKET FOR ANTIBODY FRAGMENTS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 31 ASIA PACIFIC: MARKET FOR ANTIBODY FRAGMENTS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 32 LATIN AMERICA: MARKET FOR ANTIBODY FRAGMENTS, BY COUNTRY, 2021–2028 (USD MILLION)
    6.5 BISPECIFIC ANTIBODIES 
           6.5.1 MINIMAL SIDE EFFECTS OF BISPECIFIC ANTIBODIES DUE TO TARGETED APPROACH TO FUEL ADOPTION
                    TABLE 33 APPROVED BISPECIFIC ANTIBODIES
                    TABLE 34 ANTIBODY THERAPEUTICS MARKET FOR BISPECIFIC ANTIBODIES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 35 NORTH AMERICA: MARKET FOR BISPECIFIC ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 36 EUROPE: MARKET FOR BISPECIFIC ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 37 ASIA PACIFIC: MARKET FOR BISPECIFIC ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 38 LATIN AMERICA: MARKET FOR BISPECIFIC ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
    6.6 OTHER NOVEL ANTIBODY THERAPIES 
          TABLE 39 APPROVED NOVEL ANTIBODY THERAPIES
          TABLE 40 MARKET FOR OTHER NOVEL ANTIBODY THERAPIES, BY REGION, 2021–2028 (USD MILLION)
          TABLE 41 NORTH AMERICA: MARKET FOR OTHER NOVEL ANTIBODY THERAPIES, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 42 EUROPE: MARKET FOR OTHER NOVEL ANTIBODY THERAPIES, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 43 ASIA PACIFIC: MARKET FOR OTHER NOVEL ANTIBODY THERAPIES, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 44 LATIN AMERICA: MARKET FOR OTHER NOVEL ANTIBODY THERAPIES, BY COUNTRY, 2021–2028 (USD MILLION)
 
7 ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA (Page No. - 91)
    7.1 INTRODUCTION 
          TABLE 45 ANTIBODY THERAPEUTICS INDUSTRY, BY DISEASE AREA, 2021–2028 (USD MILLION)
    7.2 AUTOIMMUNE & INFLAMMATORY DISEASES 
           7.2.1 LARGE NUMBER OF MARKETED ANTIBODY THERAPEUTICS AND STRONG PIPELINE TO DRIVE MARKET
                    TABLE 46 MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 47 NORTH AMERICA: MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 48 EUROPE: MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 49 ASIA PACIFIC: MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 50 LATIN AMERICA: MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
    7.3 ONCOLOGY 
           7.3.1 INITIATIVES BY MARKET PLAYERS TO DEVELOP ANTIBODY THERAPIES FOR CANCER INDICATIONS TO SUPPORT GROWTH
                    TABLE 51 ANTIBODY THERAPEUTICS INDUSTRY FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 52 NORTH AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 53 EUROPE: MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 54 ASIA PACIFIC: MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 55 LATIN AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
    7.4 HEMATOLOGY 
           7.4.1 GROWING PRODUCT ADOPTION TO SUPPORT MARKET GROWTH
                    TABLE 56 MARKET FOR HEMATOLOGY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 57 NORTH AMERICA: MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 58 EUROPE: MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 59 ASIA PACIFIC: MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 60 LATIN AMERICA: MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
    7.5 INFECTIOUS DISEASES 
           7.5.1 GROWING RESEARCH FOCUS ON INFECTIOUS DISEASES TO FUEL MARKET GROWTH
                    TABLE 61 ANTIBODY THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 62 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 63 EUROPE: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 64 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 65 LATIN AMERICA: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
    7.6 OSTEOLOGY 
           7.6.1 GROWING FOCUS ON OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN TO SUPPORT GROWTH
                    TABLE 66 MARKET FOR OSTEOLOGY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 67 NORTH AMERICA: MARKET FOR OSTEOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 68 EUROPE: MARKET FOR OSTEOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 69 ASIA PACIFIC: MARKET FOR OSTEOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 70 LATIN AMERICA: MARKET FOR OSTEOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
    7.7 IMMUNOLOGY 
           7.7.1 GROWING USE OF HUMORAL IMMUNODEFICIENCY ANTIBODY THERAPEUTICS TO PROPEL MARKET GROWTH
                    TABLE 71 MARKET FOR IMMUNOLOGY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 72 NORTH AMERICA: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 73 EUROPE: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 74 ASIA PACIFIC: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 75 LATIN AMERICA: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
    7.8 NEUROLOGY 
           7.8.1 PRESENCE OF SEVERAL MONOCLONAL ANTIBODIES FOR NEUROLOGICAL CONDITIONS TO FUEL MARKET GROWTH
                    TABLE 76 MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 77 NORTH AMERICA: MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 78 EUROPE: MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 79 ASIA PACIFIC: MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 80 LATIN AMERICA: MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
    7.9 OTHER DISEASE AREAS 
          TABLE 81 MARKET FOR OTHER DISEASE AREAS, BY REGION, 2021–2028 (USD MILLION)
          TABLE 82 NORTH AMERICA: MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 83 EUROPE: MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 84 ASIA PACIFIC: MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 85 LATIN AMERICA: MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
 
8 ANTIBODY THERAPEUTICS MARKET, BY SOURCE (Page No. - 113)
    8.1 INTRODUCTION 
          TABLE 86 ANTIBODY THERAPEUTICS INDUSTRY, BY SOURCE, 2021–2028 (USD MILLION)
    8.2 HUMAN 
           8.2.1 REDUCED IMMUNOGENICITY OF HUMAN-SOURCED ANTIBODIES TO DRIVE GROWTH
                    TABLE 87 MARKET FOR HUMAN SOURCES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 88 NORTH AMERICA: MARKET FOR HUMAN SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 89 EUROPE: MARKET FOR HUMAN SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 90 ASIA PACIFIC: MARKET FOR HUMAN SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 91 LATIN AMERICA: MARKET FOR HUMAN SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)
    8.3 HUMANIZED 
           8.3.1 EFFECTIVENESS OF HUMANIZED ANTIBODY THERAPEUTICS AGAINST CANCER AND AUTOIMMUNE & INFLAMMATORY DISORDERS TO DRIVE DEMAND
                    TABLE 92 ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 93 NORTH AMERICA: MARKET FOR HUMANIZED SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 94 EUROPE: MARKET FOR HUMANIZED SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 95 ASIA PACIFIC: MARKET FOR HUMANIZED SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 96 LATIN AMERICA: MARKET FOR HUMANIZED SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)
    8.4 CHIMERIC 
           8.4.1 INTRODUCTION OF HYBRID DESIGNS RESULTING IN IMPROVED EFFICACY TO SUPPORT MARKET GROWTH
                    TABLE 97 ANTIBODY THERAPEUTICS INDUSTRY FOR CHIMERIC SOURCES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 98 NORTH AMERICA: MARKET FOR CHIMERIC SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 99 EUROPE: MARKET FOR CHIMERIC SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 100 ASIA PACIFIC: MARKET FOR CHIMERIC SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 101 LATIN AMERICA: MARKET FOR CHIMERIC SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)
    8.5 OTHER SOURCES 
          TABLE 102 MARKET FOR OTHER SOURCES, BY REGION, 2021–2028 (USD MILLION)
          TABLE 103 NORTH AMERICA: MARKET FOR OTHER SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 104 EUROPE: MARKET FOR OTHER SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 105 ASIA PACIFIC: MARKET FOR OTHER SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 106 LATIN AMERICA: MARKET FOR OTHER SOURCES, BY COUNTRY, 2021–2028 (USD MILLION)
 
9 ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION (Page No. - 125)
    9.1 INTRODUCTION 
          TABLE 107 ANTIBODY THERAPEUTICS INDUSTRY, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
    9.2 INTRAVENOUS 
           9.2.1 EFFECTIVENESS OF INTRAVENOUS PRODUCTS TO SUPPORT MARKET GROWTH
                    TABLE 108 MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 109 NORTH AMERICA: MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 110 EUROPE: MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 111 ASIA PACIFIC: MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 112 LATIN AMERICA: MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
    9.3 SUBCUTANEOUS 
           9.3.1 ADVANTAGES SUCH AS FASTER ONSET OF THERAPEUTIC EFFECT TO BOOST DEMAND
                    TABLE 113 ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 114 NORTH AMERICA: MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 115 EUROPE: MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 116 ASIA PACIFIC: MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 117 LATIN AMERICA: MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
    9.4 OTHER ROUTES OF ADMINISTRATION 
          TABLE 118 MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION)
          TABLE 119 NORTH AMERICA: MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 120 EUROPE: MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 121 ASIA PACIFIC: MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 122 LATIN AMERICA: MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
 
10 ANTIBODY THERAPEUTICS MARKET, BY END USER (Page No. - 134)
     10.1 INTRODUCTION 
             TABLE 123 ANTIBODY THERAPEUTICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
     10.2 HOSPITALS 
             10.2.1 AVAILABILITY OF ADVANCED FACILITIES AND SUPPORT TO DRIVE MARKET
                        TABLE 124 MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 125 NORTH AMERICA: MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 126 EUROPE: MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 127 ASIA PACIFIC: MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 128 LATIN AMERICA: MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION)
     10.3 LONG-TERM CARE FACILITIES 
             10.3.1 ADVANTAGES SUCH AS SPECIALIZED CARE AND MONITORING TO SUPPORT MARKET GROWTH
                        TABLE 129 ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 130 NORTH AMERICA: MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 131 EUROPE: MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 132 ASIA PACIFIC: MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 133 LATIN AMERICA: MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2021–2028 (USD MILLION)
     10.4 OTHER END USERS 
             TABLE 134 MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
             TABLE 135 NORTH AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 136 EUROPE: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 137 ASIA PACIFIC: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 138 LATIN AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
 
11 ANTIBODY THERAPEUTICS MARKET, BY REGION (Page No. - 142)
     11.1 INTRODUCTION 
             TABLE 139 ANTIBODY THERAPEUTICS INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
     11.2 NORTH AMERICA 
             FIGURE 28 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET SNAPSHOT
             TABLE 140 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 141 NORTH AMERICA: MARKET, BY FORMAT, 2021–2028 (USD MILLION)
             TABLE 142 NORTH AMERICA: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
             TABLE 143 NORTH AMERICA: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
             TABLE 144 NORTH AMERICA: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
             TABLE 145 NORTH AMERICA: ANTIBODY THERAPEUTICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             11.2.1 US
                        11.2.1.1 Growing FDA approvals for novel antibody therapeutics to drive market
                                      TABLE 146 US FDA ANTIBODY THERAPEUTIC PRODUCT APPROVALS
                                      TABLE 147 US: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)
                                      TABLE 148 US: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                                      TABLE 149 US: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                                      TABLE 150 US: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 151 US: ANTIBODY THERAPEUTICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             11.2.2 CANADA
                        11.2.2.1 Growing cancer burden and investments in antibody research to support market growth
                                      TABLE 152 CANADA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)
                                      TABLE 153 CANADA: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                                      TABLE 154 CANADA: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                                      TABLE 155 CANADA: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 156 CANADA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.2.3 NORTH AMERICA: RECESSION IMPACT
     11.3 EUROPE 
             FIGURE 29 EUROPE: ANTIBODY THERAPEUTICS MARKET SNAPSHOT
             TABLE 157 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 158 EUROPE: MARKET, BY FORMAT, 2021–2028 (USD MILLION)
             TABLE 159 EUROPE: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
             TABLE 160 EUROPE: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
             TABLE 161 EUROPE: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
             TABLE 162 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.1 GERMANY
                        11.3.1.1 Rising incidence of cancer to drive market
                                      TABLE 163 GERMANY: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)
                                      TABLE 164 GERMANY: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                                      TABLE 165 GERMANY: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                                      TABLE 166 GERMANY: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 167 GERMANY: ANTIBODY THERAPEUTICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             11.3.2 UK
                        11.3.2.1 Growing research initiatives to support market growth
                                      TABLE 168 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
                                      TABLE 169 UK: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)
                                      TABLE 170 UK: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                                      TABLE 171 UK: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                                      TABLE 172 UK: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 173 UK: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.3 FRANCE
                        11.3.3.1 Favorable reimbursement policies to drive growth
                                      TABLE 174 FRANCE: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)
                                      TABLE 175 FRANCE: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                                      TABLE 176 FRANCE: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                                      TABLE 177 FRANCE: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 178 FRANCE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.4 ITALY
                        11.3.4.1 Growing regulatory approvals for antibody therapeutics to support growth
                                      TABLE 179 ITALY: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)
                                      TABLE 180 ITALY: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                                      TABLE 181 ITALY: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                                      TABLE 182 ITALY: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 183 ITALY: ANTIBODY THERAPEUTICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             11.3.5 SPAIN
                        11.3.5.1 Growing prevalence of cancer to drive market
                                      TABLE 184 SPAIN: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)
                                      TABLE 185 SPAIN: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                                      TABLE 186 SPAIN: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                                      TABLE 187 SPAIN: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 188 SPAIN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.6 REST OF EUROPE
                        TABLE 189 REST OF EUROPE: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)
                        TABLE 190 REST OF EUROPE: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                        TABLE 191 REST OF EUROPE: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                        TABLE 192 REST OF EUROPE: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                        TABLE 193 REST OF EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.7 EUROPE: RECESSION IMPACT
     11.4 ASIA PACIFIC 
             TABLE 194 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 195 ASIA PACIFIC: MARKET, BY FORMAT, 2021–2028 (USD MILLION)
             TABLE 196 ASIA PACIFIC: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
             TABLE 197 ASIA PACIFIC: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
             TABLE 198 ASIA PACIFIC: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
             TABLE 199 ASIA PACIFIC: ANTIBODY THERAPEUTICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             11.4.1 CHINA
                        11.4.1.1 Growing demand for therapeutic products to support growth
                                      TABLE 200 CHINA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)
                                      TABLE 201 CHINA: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                                      TABLE 202 CHINA: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                                      TABLE 203 CHINA: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 204 CHINA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.2 JAPAN
                        11.4.2.1 Growing access to quality healthcare to boost market
                                      TABLE 205 JAPAN: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)
                                      TABLE 206 JAPAN: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                                      TABLE 207 JAPAN: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                                      TABLE 208 JAPAN: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 209 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.3 INDIA
                        11.4.3.1 Increasing burden of chronic diseases and growing R&D initiatives to drive market
                                      TABLE 210 INDIA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)
                                      TABLE 211 INDIA: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                                      TABLE 212 INDIA: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                                      TABLE 213 INDIA: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 214 INDIA: ANTIBODY THERAPEUTICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             11.4.4 SOUTH KOREA
                        11.4.4.1 Favorable government initiatives to propel market
                                      TABLE 215 SOUTH KOREA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)
                                      TABLE 216 SOUTH KOREA: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                                      TABLE 217 SOUTH KOREA: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                                      TABLE 218 SOUTH KOREA: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 219 SOUTH KOREA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.5 REST OF ASIA PACIFIC
                        TABLE 220 REST OF ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)
                        TABLE 221 REST OF ASIA PACIFIC: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                        TABLE 222 REST OF ASIA PACIFIC: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                        TABLE 223 REST OF ASIA PACIFIC: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                        TABLE 224 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.6 ASIA PACIFIC: RECESSION IMPACT
     11.5 LATIN AMERICA 
             TABLE 225 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 226 LATIN AMERICA: MARKET, BY FORMAT, 2021–2028 (USD MILLION)
             TABLE 227 LATIN AMERICA: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
             TABLE 228 LATIN AMERICA: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
             TABLE 229 LATIN AMERICA: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
             TABLE 230 LATIN AMERICA: ANTIBODY THERAPEUTICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             11.5.1 BRAZIL
                        11.5.1.1 Growing demand for therapeutics against chronic diseases to drive market
                                      TABLE 231 BRAZIL: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)
                                      TABLE 232 BRAZIL: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                                      TABLE 233 BRAZIL: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                                      TABLE 234 BRAZIL: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 235 BRAZIL: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.5.2 REST OF LATIN AMERICA
                        TABLE 236 REST OF LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)
                        TABLE 237 REST OF LATIN AMERICA: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                        TABLE 238 REST OF LATIN AMERICA: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                        TABLE 239 REST OF LATIN AMERICA: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                        TABLE 240 REST OF LATIN AMERICA: ANTIBODY THERAPEUTICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             11.5.3 LATIN AMERICA: RECESSION IMPACT
     11.6 MIDDLE EAST 
             11.6.1 DEVELOPING HEALTHCARE INFRASTRUCTURE TO PROPEL MARKET
                        TABLE 241 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)
                        TABLE 242 MIDDLE EAST: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                        TABLE 243 MIDDLE EAST: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                        TABLE 244 MIDDLE EAST: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                        TABLE 245 MIDDLE EAST: ANTIBODY THERAPEUTICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             11.6.2 MIDDLE EAST: RECESSION IMPACT
     11.7 AFRICA 
             11.7.1 INCREASING PUBLIC AND PRIVATE INVESTMENTS IN HEALTHCARE TO SUPPORT MARKET GROWTH
                        TABLE 246 AFRICA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION)
                        TABLE 247 AFRICA: MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)
                        TABLE 248 AFRICA: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                        TABLE 249 AFRICA: MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                        TABLE 250 AFRICA: ANTIBODY THERAPEUTICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             11.7.2 AFRICA: RECESSION IMPACT
 
12 COMPETITIVE LANDSCAPE (Page No. - 204)
     12.1 INTRODUCTION 
     12.2 KEY STRATEGIES/RIGHT TO WIN 
             FIGURE 30 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ANTIBODY THERAPEUTICS MARKET
     12.3 MARKET SHARE ANALYSIS 
             FIGURE 31 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022
             TABLE 251 DEGREE OF COMPETITION: ANTIBODY THERAPEUTICS INDUSTRY
     12.4 MARKET REVENUE ANALYSIS 
             FIGURE 32 REVENUE ANALYSIS FOR KEY COMPANIES, 2020–2022
     12.5 COMPANY EVALUATION MATRIX 
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
                        FIGURE 33 COMPANY EVALUATION MATRIX, 2022
             12.5.5 COMPANY FOOTPRINT
                        12.5.5.1 Product footprint
                                      TABLE 252 PRODUCT FOOTPRINT OF KEY PLAYERS
                        12.5.5.2 Regional footprint
                                      TABLE 253 REGIONAL FOOTPRINT OF KEY PLAYERS
     12.6 START-UP/SME EVALUATION MATRIX 
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 RESPONSIVE COMPANIES
             12.6.3 DYNAMIC COMPANIES
             12.6.4 STARTING BLOCKS
                        FIGURE 34 START-UP/SME EVALUATION MATRIX, 2022
             12.6.5 COMPETITIVE BENCHMARKING
                        TABLE 254 DETAILED LIST OF KEY START-UPS/SMES
                        TABLE 255 COMPETITIVE BENCHMARKING OF START-UPS/SMES
     12.7 COMPETITIVE SCENARIOS AND TRENDS 
             12.7.1 PRODUCT APPROVALS
                        TABLE 256 PRODUCT APPROVALS, JANUARY 2020–SEPTEMBER 2023
             12.7.2 DEALS
                        TABLE 257 DEALS, JANUARY 2020–SEPTEMBER 2023
             12.7.3 OTHER DEVELOPMENTS
                        TABLE 258 OTHER DEVELOPMENTS, JANUARY 2020–SEPTEMBER 2023
 
13 COMPANY PROFILES (Page No. - 217)
(Business overview, Products/Services/Solutions offered, Recent developments & MnM View)*
     13.1 KEY PLAYERS 
             13.1.1 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 259 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
                        FIGURE 35 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
                        TABLE 260 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES
                        TABLE 261 F. HOFFMANN-LA ROCHE LTD.: PRODUCT APPROVALS
                        TABLE 262 F. HOFFMANN-LA ROCHE LTD.: DEALS
             13.1.2 ABBVIE INC.
                        TABLE 263 ABBVIE INC.: COMPANY OVERVIEW
                        FIGURE 36 ABBVIE INC.: COMPANY SNAPSHOT (2022)
                        TABLE 264 ABBVIE INC.: PRODUCT APPROVALS
                        TABLE 265 ABBVIE INC.: DEALS
             13.1.3 JOHNSON & JOHNSON
                        TABLE 266 JOHNSON & JOHNSON: COMPANY OVERVIEW
                        FIGURE 37 JOHNSON & JOHNSON: COMPANY SNAPSHOT
                        TABLE 267 JOHNSON & JOHNSON: PRODUCT APPROVALS
             13.1.4 MERCK KGAA
                        TABLE 268 MERCK KGAA: COMPANY OVERVIEW
                        FIGURE 38 MERCK KGAA: COMPANY SNAPSHOT (2022)
                        TABLE 269 MERCK KGAA: PRODUCT APPROVALS
                        TABLE 270 MERCK KGAA: OTHER DEVELOPMENTS
             13.1.5 BRISTOL-MYERS SQUIBB
                        TABLE 271 BRISTOL-MYERS SQUIBB: COMPANY OVERVIEW
                        FIGURE 39 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT (2022)
                        TABLE 272 BRISTOL-MYERS SQUIBB: PRODUCT APPROVALS
                        TABLE 273 BRISTOL-MYERS SQUIBB: DEALS
                        TABLE 274 BRISTOL-MYERS SQUIBB: OTHER DEVELOPMENTS
             13.1.6 ASTRAZENECA
                        TABLE 275 ASTRAZENECA: COMPANY OVERVIEW
                        FIGURE 40 ASTRAZENECA: COMPANY SNAPSHOT (2022)
                        TABLE 276 ASTRAZENECA: DEALS
                        TABLE 277 ASTRAZENECA: PRODUCT APPROVALS
             13.1.7 SANOFI
                        TABLE 278 SANOFI: COMPANY OVERVIEW
                        FIGURE 41 SANOFI: COMPANY SNAPSHOT (2022)
                        TABLE 279 SANOFI: PRODUCT APPROVALS
                        TABLE 280 SANOFI: DEALS
             13.1.8 REGENERON PHARMACEUTICALS INC.
                        TABLE 281 REGENERON PHARMACEUTICALS INC.: COMPANY OVERVIEW
                        FIGURE 42 REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT
                        TABLE 282 REGENERON PHARMACEUTICALS INC.: DEALS
                        TABLE 283 REGENERON PHARMACEUTICALS INC.: PRODUCT APPROVALS
             13.1.9 NOVARTIS AG
                        TABLE 284 NOVARTIS AG: COMPANY OVERVIEW
                        FIGURE 43 NOVARTIS AG: COMPANY SNAPSHOT (2022)
                        TABLE 285 NOVARTIS AG: DEALS
                        TABLE 286 NOVARTIS AG: PRODUCT APPROVALS
                        TABLE 287 NOVARTIS AG: OTHER DEVELOPMENTS
             13.1.10 AMGEN INC.
                        TABLE 288 AMGEN INC.: COMPANY OVERVIEW
                        FIGURE 44 AMGEN INC.: COMPANY SNAPSHOT (2022)
                        TABLE 289 AMGEN INC.: DEALS
                        TABLE 290 AMGEN INC.: PRODUCT APPROVALS
                        TABLE 291 AMGEN INC.: OTHER DEVELOPMENTS
             13.1.11 BIOGEN
                        TABLE 292 BIOGEN: COMPANY OVERVIEW
                        FIGURE 45 BIOGEN INC.: COMPANY SNAPSHOT (2022)
                        TABLE 293 BIOGEN: PRODUCT APPROVALS
                        TABLE 294 BIOGEN: DEALS
             13.1.12 TAKEDA PHARMACEUTICAL COMPANY LIMITED
                        TABLE 295 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW
                        FIGURE 46 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022)
                        TABLE 296 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT APPROVALS
             13.1.13 PFIZER INC.
                        TABLE 297 PFIZER INC.: COMPANY OVERVIEW
                        FIGURE 47 PFIZER INC.: COMPANY SNAPSHOT
                        TABLE 298 PFIZER INC.: PRODUCT APPROVALS
             13.1.14 ELI LILLY AND COMPANY
                        TABLE 299 ELI LILLY AND COMPANY: COMPANY OVERVIEW
                        FIGURE 48 ELI LILLY AND COMPANY: COMPANY SNAPSHOT
                        TABLE 300 ELI LILLY AND COMPANY: PRODUCT APPROVALS
                        TABLE 301 ELI LILLY AND COMPANY: DEALS
                        TABLE 302 ELI LILLY AND COMPANY: OTHER DEVELOPMENTS
             13.1.15 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
                        TABLE 303 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW
                        FIGURE 49 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2022)
                        TABLE 304 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS
                        TABLE 305 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT APPROVALS
                        TABLE 306 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OTHER DEVELOPMENTS
             13.1.16 GLAXOSMITHKLINE PLC
                        TABLE 307 GLAXOSMITHKLINE PLC: COMPANY OVERVIEW
                        FIGURE 50 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2022)
                        TABLE 308 GLAXOSMITHKLINE PLC: DEALS
                        TABLE 309 GLAXOSMITHKLINE PLC: PRODUCT APPROVALS
                        TABLE 310 GLAXOSMITHKLINE PLC: OTHER DEVELOPMENTS
             13.1.17 UCB S.A.
                        TABLE 311 UCB S.A.: COMPANY OVERVIEW
                        FIGURE 51 UCB S.A.: COMPANY SNAPSHOT (2022)
                        TABLE 312 UCB S.A.: DEALS
                        TABLE 313 UCB S.A.: PRODUCT APPROVALS
*Details on Business overview, Products/Services/Solutions offered, Recent developments & MnM View might not be captured in case of unlisted companies.
     13.2 OTHER PLAYERS 
             13.2.1 EMERGENT BIOSOLUTIONS INC.
             13.2.2 Y-MABS THERAPEUTICS, INC.
             13.2.3 TEVA PHARMACEUTICAL INDUSTRIES LTD.
             13.2.4 ULTRAGENYX PHARMACEUTICAL INC.
             13.2.5 H. LUNDBECK A/S
             13.2.6 CELLTRION INC.
             13.2.7 MACROGENICS, INC.
             13.2.8 MORPHOSYS AG
 
14 APPENDIX (Page No. - 297)
     14.1 DISCUSSION GUIDE 
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     14.3 CUSTOMIZATION OPTIONS 
     14.4 RELATED REPORTS 
     14.5 AUTHOR DETAILS 

This study involved four major activities in estimating the historic, current and forecasted size of the antibody therapeutics market. Exhaustive secondary research was carried out to collect information on the market, and its peer markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments. The revenues for mapped antibody therapeutics products approved till 2023 and clinical pipeline data with estimated launch dates between 2024 and 2027 have been considered for market estimation.

Secondary Research

The secondary sources referred to for this research study include publications from public sources, such as the World Health Organization (WHO), National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), National Center for Biotechnology Information (NCBI), BioPharm International, ScienceDirect, Purple Book, and clinicaltrial.gov, among others. Secondary sources also include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global antibody therapeutics market, which was validated through primary research.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.

Antibody  Therapeutics Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Bottom-up approach was used to estimate and validate the total size of the antibody therapeutics market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The antibody therapeutics products approved by key regulatory authorities so far and which are marketed were mapped along with their revenues from 2020 to 2022 to evaluate the total market size
  • Study about the key industry trends and issues defining the strategic growth objectives of market players was conducted
  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the antibody therapeutics business of leading players (approved product revenues) have been validated through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Global Antibody Therapeutics Market Size: Bottom-Up Approach

Antibody  Therapeutics Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Therapeutic antibodies are targeted biopharmaceuticals that trigger a biological response. Therapeutic antibodies are drugs that use antibodies which play a significant role in the inherent immune system of the body. When pathogens such as bacteria and viruses invade the body, antibodies are produced from B cells, a type of immune cell, to attack foreign substances (antigens). These antibodies have the characteristics of recognizing and attacking only specific antigens.

Key Stakeholders

  • Pharmaceutical companies
  • Biotechnology companies
  • Research institutions & academic centers
  • Regulatory agencies
  • Health insurers and payers
  • Private & government-funding organizations  

Report Objectives

  • To define, describe, and forecast the global antibody therapeutics market by format, disease area, route of administration, source, end user and region
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall antibody therapeutics market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To provide detailed information regarding the major factors influencing the market growth, such as drivers, restraints, opportunities, and challenges
  • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
  • To strategically analyze the market structure and profile the key players of the global antibody therapeutics market and comprehensively analyze their core competencies
  • To track and analyze competitive developments such as expansions, acquisitions, partnerships, collaborations, agreements, and product launches in the antibody therapeutics market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Company Information

  • Twenty five company profiles
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization
Report Code
PH 8876
Published ON
Dec, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Antibody Therapeutics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback